Concord Biotech Ltd share price logo

Concord Biotech Share Price

NSE: CONCORDBIO

BSE: 543960

Small Cap

Healthcare Sector

₹1230.90

+154.80

(+14.39%)

as on

bell
The current prices are delayed by 15 mins, login to check live prices.

Tech Chart

Concord Biotech Stock Performance

as on February 25, 2026 at 9:31 pm IST

  • Day's Low

    Day's High

    ₹1,072.70
    ₹1,291.30
    downward going graph

    12.85%

    Downside

    4.91%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    ₹1,072.70
    ₹2,150.40
    downward going graph

    12.85%

    Downside

    74.70%

    Upside

    downward going graph

Concord Biotech share price movements today

Previous Close
₹1,076.10
Open
₹1,075.00
Volume
1.14Cr
Upper Circuit
₹1,291.30
Lower Circuit
₹860.90
Day's Low - High
₹1,072.70 - ₹1,291.30
52 Week Low - High
₹1,072.70 - ₹2,150.40

Concord Biotech Historical Returns

1 Month Return
-11.94 %
3 Month Return
-23.26 %
1 Year Return
-33.93 %
3 Year Return
+ 14.14 %
5 Year Return
+ 14.14 %

Concord Biotech Fundamentals

as on February 25, 2026 at 4:01 pm IST

Market Cap

₹11,257.75 Cr

Return on Equity (ROE)

22.35

PE Ratio (TTM)

36.18

Return on capital employed (ROCE)

29.62

Industry PE ratio

41.66

Beta (LTM)

0.64

P/B Ratio

9.67

Dividend Yield

0.52

PEG Ratio

-24.95

Quarterly Earnings Growth YOY

-16.17

EPS (TTM)

35.52

Sector

Pharmaceuticals

Book Value

173.27

Technical Analysis

Bullish

View Technical Analysis

Concord Biotech Stock Valuation

as on February 25, 2026 at 4:01 pm IST

Concord Biotech in the last 5 years

  • Overview

  • Trends

Lowest (36.18x)

February 24, 2026

Today (36.18x)

February 24, 2026

Industry (41.66x)

February 24, 2026

Highest (86.91x)

September 20, 2024

LowHigh

Today’s Price to Earnings Ratio: 36.18x

Concord Biotech Ltd vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Concord Biotech with its industry peers.

Company
Analyst View
Market Cap(in ₹ Cr)
5 Year CAGRDebt to Asset Ratio
Net Profit(in ₹ Cr)
Yearly Revenue(in ₹ Cr)
Concord Biotech Ltd image
Concord Biotech Ltd
BUY11,257.752.83%0.503711,200
Lasa Supergenerics Ltd image
Lasa Supergenerics Ltd
NA41.38-17.6%0.00-22104
Phaarmasia Ltd image
Phaarmasia Ltd
NA66.1849.34%0.00-224
Remus Pharmaceuticals Ltd image
Remus Pharmaceuticals Ltd
NA800.1340.46%0.5838620
Gujarat Terce Laboratories Ltd image
Gujarat Terce Laboratories Ltd
NA29.6481.63%0.00-150
See all

Market expectation of Concord Biotech Stock

Common consensus of the market based on various publicly available news, publications,brokerage expectation and market data

BUY

50.00%

Buy

50.00%

Hold

0.00%

Sell

Concord Biotech Stock’s Investor Sentiment and Interest

Investment in Concord Biotech Ltd Shares on INDmoney has grown by 627.27% over the past 30 days, indicating increased transactional activity.

Time period: to

Change:627.27% versus previous 30 day period

Search interest for Concord Biotech Ltd Stock has increased by 106% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:106% versus previous 30 day period

Concord Biotech Ltd Quarterly Profit & Loss

Figures in Rupees Crores

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Sales
272.59
194.83
262.35
240.8
318.97
215.8
310.18
244.22
429.88
203.99
247.06
277.77
Other Income
12.2
12.68
8.13
11.21
10.81
11.66
10.03
16.56
9.38
15.17
15.64
9.98
Total Income
284.79
207.51
270.47
252
329.78
227.46
320.21
260.78
439.27
219.16
262.7
287.74
Expenses
145.54
122.68
146.63
134.87
186.88
134.52
176.46
146.27
241.01
142.59
158.57
182.76
Operating Profit
127.05
72.15
115.72
105.93
132.09
81.28
133.72
97.95
188.87
61.4
88.49
95.01
Operating Profit Margin %
46.61%
37.03%
44.11%
43.99%
41.41%
37.66%
43.11%
40.11%
43.94%
30.1%
35.82%
34.2%
Profit Before Interest, Tax and Depreciation
139.25
84.83
123.84
117.14
142.9
92.94
143.75
114.51
198.26
76.57
104.13
104.98
Interest
1.45
0.75
0.84
0.5
0.46
0.24
0.1
0.1
0.1
0.06
0.06
0.08
Depreciation
14.18
13.04
13.3
13.54
13.72
13.18
13.31
13.26
14.62
17.78
18.39
18.75
Profit Before Tax
123.62
71.04
109.7
103.1
128.72
79.52
130.34
101.15
183.54
58.73
85.68
86.15
Tax Paid
32.12
16.54
28.69
25.53
33.71
19.92
34.59
25.23
43.16
14.68
22.63
22.52
Profit After Tax
91.49
54.49
81.02
77.57
95.02
59.59
95.74
75.92
140.39
44.06
63.06
63.64
Total Net profit including share of profit / Loss from associate company
91.49
54.49
81.02
77.57
95.02
59.59
95.74
75.92
140.39
44.06
63.06
63.64
EPS
8.75
5.21
7.74
7.41
9.08
5.7
9.15
7.26
13.42
4.21
6.03
6.08
Actual EPS
8.75
5.21
7.74
7.41
9.08
5.7
9.15
7.26
13.42
4.21
6.03
6.08
Adjusted EPS
8.75
5.21
7.74
7.41
9.08
5.7
9.15
7.26
13.42
4.21
6.03
6.08
Diluted EPS
8.75
5.21
7.74
7.41
9.08
5.7
9.15
7.26
13.42
4.21
6.03
6.08

Concord Biotech Ltd Annual Profit & Loss

Figures in Rupees Crores

Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Sales
616.94
712.93
853.17
1,016.94
1,200.09
Other Income
13.81
23.42
37.27
37.15
44.45
Total Income
630.75
736.35
890.44
1,054.09
1,244.53
Expenses
289.84
443.3
509.88
585.38
695.08
Operating Profit
327.1
269.63
343.29
431.56
505.01
Operating Profit Margin %
53.02%
37.82%
40.24%
42.44%
42.08%
Profit Before Interest, Tax and Depreciation
340.91
293.05
380.56
468.71
549.46
Interest
0.67
5.48
4.51
2.55
0.53
Depreciation
27.52
50.05
54.03
53.59
54.37
Profit Before Tax
312.72
237.52
322.02
412.57
494.56
Tax Paid
77.83
62.58
81.93
104.46
122.91
Profit After Tax
234.89
174.93
240.09
308.1
371.64
Total Net profit including share of profit / Loss from associate company
234.89
174.93
240.09
308.1
371.64
EPS
246.92
183.34
22.95
29.45
35.52
Actual EPS
246.92
183.34
22.95
29.45
35.52
Adjusted EPS
22.45
16.67
22.95
29.45
35.52
Diluted EPS
246.92
183.34
22.95
29.45
35.52

Concord Biotech Ltd Cash Flow

Figures in Rupees Crores

Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Net Cash from Operating Activities
155.09
166.81
207.47
246
265.47
244.52
Cash Flow from Investing Activities
-113.93
-195.45
-111.77
-157.95
-154.61
-159.99
Cash Flow from Financing Activities
-42.52
31.36
-100.15
-85.22
-99.22
-98.77
Net Cash Flow
-1.35
2.74
-4.48
2.83
11.64
-14.24

Concord Biotech Stock Shareholding Pattern

Numbers in percentages

Aug 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Promoters
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
44.08%
DII
4.89%
8.18%
8.13%
8.46%
10.4%
9.89%
9.66%
9.16%
8.87%
9.55%
9.58%
FII
0%
7.3%
0%
6.48%
7.11%
8.1%
8.33%
9.35%
9.11%
8.03%
7.58%
Public
45.92%
40.44%
40.46%
40.97%
38.41%
37.93%
37.93%
37.41%
37.95%
38.33%
38.76%
Total Outstanding Shares
10,46,16,204
10,46,16,204
10,46,16,204
10,46,16,204
10,46,16,204
10,46,16,204
10,46,16,204
10,46,16,204
10,46,16,204
10,46,16,204
10,46,16,204
Total Shareholders
3,77,572
1,00,927
87,486
83,296
80,737
84,298
82,004
81,219
82,045
82,650
81,815

Mutual Funds that own Concord Biotech Stock

Check out the Mutual Funds with significant holdings in Concord Biotech.

Concord Biotech Corporate Actions

View detailed summary of the earnings and dividend history of Concord Biotech.

  • Concord Biotech Ltd Earnings Results

    Concord Biotech Ltd’s net profit fell -15.07% since last year same period to ₹64.48Cr in the Q3 2025-2026. On a quarterly growth basis, Concord Biotech Ltd has generated 1.42% jump in its net profits since last 3-months.

    Read More about Earnings Results

  • Concord Biotech Ltd Dividends May,2025

    In the quarter ending March 2025, Concord Biotech Ltd has declared dividend of ₹10.70 per share on 29 May 2025 - translating a dividend yield of 0.99%.

    Read More about Dividends

Indices Featuring Concord Biotech Stock

Check stock indices that include Concord Biotech.

S&P BSE 250 SmallCap

₹6,347.97

0.48 (▲30.54%)

BSE 500

₹36,679.75

0.41 (▲149.66%)

Nifty MidSmallcap 400

₹19,758.30

0.64 (▲125.45%)

S&P BSE 400 MidSmallCap

₹11,786.31

0.61 (▲71.60%)

BSE Healthcare

₹44,013.01

1.35 (▲584.66%)

Nifty Smallcap 250

₹16,035.70

0.64 (▲102.65%)

Nifty 500

₹23,403.80

0.43 (▲99.20%)

Insights on Concord Biotech Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 219.16 Cr → 287.74 Cr (in ₹), with an average increase of 12.6% per quarter

  • imgPOSITIVE IMPACT

    Retail Holding Up

    img

    Retail Investor have increased holdings from 38.33% to 38.76% in Dec 2025 quarter

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, 44.06 Cr → 64.48 Cr (in ₹), with an average increase of 16.1% per quarter

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 44.08% of holdings in Dec 2025 quarter

  • imgNEGATIVE IMPACT

    FII Holding Down

    img

    Foreign Institutions have decreased holdings from 8.03% to 7.58% in Dec 2025 quarter

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, CONCORDBIO stock has moved down by -6.4%

  • imgNEGATIVE IMPACT

    MF Holding Down

    img

    Mutual Funds have decreased holdings from 4.53% to 4.44% in Dec 2025 quarter

About Concord Biotech Ltd

Concord Biotech Ltd was originally incorporated as Servomed Pharmaceuticals Private Limited at Ahmedabad Gujarat as a Private Limited Company dated November 23 1984 issued by the Registrar of Companies. Thereafter name of the Company was changed to Concord Biotech Limited dated February 16 2001 which became a Public Company and a fresh Certificate of Incorporation dated November 7 2001 was issued by the RoC.The Company is an Indiabased biopharma and one of the leading global developers and manufacturers of select fermentationbased APIs across immunosuppressants and oncology in terms of market share based on volume in supplying to over 70 countries including regulated markets such as the United States Europe and Japan and India. Presently it is engaged in research and development manufacturing marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi and formulations facility at Valthera in Gujarat.In 2000 the Company was acquired by the Promoter Mr. Sudhir Vaid. In 2016 the Company launched formulation business in India as well as emerging markets including Nepal Mexico Indonesia Thailand Ecuador Kenya Singapore and Paraguay and have further expanded to the United States. It established a facility at Valthera Gujarat.It set up a joint venture in Japan to grow business in 2018.In 2019 the Company received two ANDA approvals. It expanded their business into critical care segment in India. It commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg. In 2020 Mycophenolate Sodium Tablets got launched in the US market.A second API manufacturing facility at Limbasi was launched which commenced operations in July 2021. As of March 31 2022 the Company had 6 fermentationbased immunosuppressant APIs including tacrolimus mycophenolate mofetil mycophenolate sodium cyclosporine sirolimus and pimecrolimus. It had 3 manufacturing facilities in the state of Gujarat India comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera which were commercialized in 2000 2021 and 2016 respectively. Their total annual installed fermentation capacity for APIs was 1250 m3 as of March 31 2022. It had a total of 41 manufacturing blocks and 387 reactors in the Dholka and Limbasi facilities. As of March 31 2022 the annual installed production capacity of formulation facility in Valthera amounted to 522.64 million units with an average dosage capability of 0.17 million tablets 0.36 million capsules and 646.46 bottles of dry syrup per shift which is defined as eight hours of production. The Company is planning to raise capital from Public by issuing o 20925652 Equity Shares through Offer for Sale..

Revenue: ₹277.77Cr as on December 2025 (Q3 FY26)
Net Profit: ₹63.64Cr as on December 2025 (Q3 FY26)
Listing date: 18 Aug, 2023
Chairperson Name: SUDHIR JAIRAM VAID
OrganisationConcord Biotech Ltd
HeadquartersAhmedabad
IndustryPharmaceuticals
CEOSUDHIR JAIRAM VAID
E-voting on sharesClick here to vote

FAQs

What is Concord Biotech share price today?

Concord Biotech share price today stands at ₹1230.9 as on at the close of the market. Concord Biotech share today touched a day high of ₹1291.3 and a low of ₹1072.7.

What is the 52 week high and 52 week low range for Concord Biotech share?

Concord Biotech touched a 52 week high of ₹2150.4 and a 52 week low of ₹1072.7. Concord Biotech share price today i.e. is closed at ₹1230.9, which is -42.76% down from its 52 week high and 14.75% up from its 52 week low.

What is Concord Biotech's market capitalisation today?

Concord Biotech market capitalisation is ₹11,257.75 Cr as on .

How to buy Concord Biotech shares?

To buy Concord Biotech shares, you need to follow these steps:

  • Open a Demat account and Trading account on INDmoney
  • Fund your Trading account
  • Search for CONCORDBIO or Concord Biotech Ltd on the INDmoney app to check live prices of the stock
  • Click on Buy or SIP to place an order to invest in Concord Biotech shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.

What is Concord Biotech trading volume today?

Concord Biotech trading volume is 1.14Cr as on . This means that 1.14Cr shares of Concord Biotech were bought and sold on the stock market during today's trading session.